安进公司 AMGN 深 沪
等待开盘 03-26 09:30:00 美东时间
353.93
+5.500
+1.58%
华盛通- 最 高358.00
- 今 开350.76
- 成交量 176.79万股
- 最 低 350.76
- 昨 收 348.43
- 总市值 1907.92亿
- 52周最高 391.29
- 市盈率 静 24.88
- 换手率 0.33%
- 52周最低 251.77
- 委 比 62.23%
- 总股本 5.39亿
- 历史最高 391.29
- 量 比 0.47
- 振 幅 2.08%
- 历史最低 -28.439
- 每 手 1
- 风险率 34.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy
Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen In...
今天 00:31
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
Royalty Pharma appoints Lucas Glass as Head of Artificial Intelligence, effective April 2026. With over a decade of experience in AI and data solutions, Glass will lead the implementation of cutting-edge AI capabilities, enhancing the company's decision-making and operational efficiency. His appointment underscores Royalty Pharma's commitment to leveraging advanced technologies to strengthen its competitive edge in the biopharmaceutical sector.
03-23 11:15
Private Credit's $1.8 Trillion Illusion Breaks: The Liquidity Crunch No One Was Ready For
A liquidity crunch is ripping through private credit as redemptions surge, AI risks surface, and hidden exposures unravel a $1.8 trillion industry once seen as a safe, high‑yield machine.
03-20 01:05
Royalty Pharma Announces Expansion of Leadership Team
Royalty Pharma appoints Greg Butz as Executive Vice President, Partnering & Investments, effective June 2026. Butz joins from Bank of America, where he was Global Co-Head of Healthcare Investment Banking. The company also promotes Chris Hite to Chairman, Partnering & Investments. Royalty Pharma specializes in acquiring and funding biopharmaceutical royalties, with a portfolio of over 35 commercial products and 19 development-stage candidates.
03-17 20:01
RFK Jr. dealt blow as judge blocks changes to childhood immunization schedule
A Massachusetts federal judge on Monday blocked major changes in recommendations for childhood vaccinations agreed upon by HHS under the leadership of Secretary Robert F. Kennedy Jr. Judge Brian Murph...
03-17 05:46
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
CytomX Therapeutics, Inc. announced positive Phase 1 data for Varseta-M in advanced colorectal cancer and plans to align with the FDA on a potential registrational trial design in late-line CRC by mid-2026. Additional Phase 1 data is expected at major medical meetings in 2026. The company also initiated a Phase 1 combination study of Varseta-M with bevacizumab and plans a Phase 1b/2 study in combination with chemotherapy by end-2026. For CX-801, ...
03-16 11:05
Amgen and GSK said to be adding products on TrumpRx
Amgen (AMGN) and GSK (GSK) will be the latest drugmakers to sell their medicines on TrumpRx as the government-run direct-to-consumer platform for pharmaceutical products continues to expand, Fox Busin...
03-14 21:48
GRAIL announces leadership transition
Cancer test developer Grail (GRAL) has named Josh Ofman, the company's president, as its new chief executive officer, effective June 1, 2026, following the retirement of its long-serving CEO, Bob Ragu...
03-13 19:48
Rapid Micro Biosystems Q4 revenue rises 37% on higher Growth Direct system placements
Rapid Micro Biosystems Q4 revenue rises 37% on higher Growth Direct system placements Overview U.S. life sciences automation firm's Q4 revenue rose 37% yr/yr to record high Q4 net loss widened and missed analyst expectations Company booked large multi-system orders from Amgen and Samsung Biologics O
03-12 19:09
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
